-$0.30 EPS Expected for Inovio Pharmaceuticals, Inc. (NASDAQ:INO) This Quarter

Brokerages forecast that Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Rating) will announce earnings of ($0.30) per share for the current quarter, according to Zacks. Three analysts have issued estimates for Inovio Pharmaceuticals’ earnings, with estimates ranging from ($0.38) to ($0.23). Inovio Pharmaceuticals posted earnings per share of ($0.39) in the same quarter last year, which would suggest a positive year over year growth rate of 23.1%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Inovio Pharmaceuticals will report full year earnings of ($1.22) per share for the current fiscal year, with EPS estimates ranging from ($1.60) to ($0.85). For the next year, analysts expect that the firm will report earnings of ($0.88) per share, with EPS estimates ranging from ($1.50) to ($0.63). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO – Get Rating) last released its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). The firm had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.66 million. Inovio Pharmaceuticals had a negative return on equity of 76.48% and a negative net margin of 20,479.29%. Inovio Pharmaceuticals’s revenue was down 46.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.27) earnings per share.

A number of equities analysts recently weighed in on the company. Oppenheimer lowered Inovio Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 11th. Cantor Fitzgerald dropped their price target on Inovio Pharmaceuticals from $6.00 to $3.00 in a research report on Wednesday, May 11th. Zacks Investment Research raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 5th. Royal Bank of Canada decreased their price target on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating on the stock in a research note on Wednesday, March 2nd. Finally, Bank of America raised Inovio Pharmaceuticals from an “underperform” rating to a “neutral” rating and boosted their price objective for the stock from $8.00 to $10.00 in a research note on Friday, January 21st. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating and six have given a hold rating to the company. According to data from MarketBeat.com, Inovio Pharmaceuticals has an average rating of “Hold” and an average target price of $10.75.

Several hedge funds and other institutional investors have recently made changes to their positions in INO. Running Point Capital Advisors LLC acquired a new stake in shares of Inovio Pharmaceuticals during the 1st quarter valued at $36,000. Smith Anglin Financial LLC bought a new position in Inovio Pharmaceuticals during the 1st quarter worth $36,000. Covestor Ltd bought a new position in shares of Inovio Pharmaceuticals in the 4th quarter worth about $42,000. CIBC Asset Management Inc bought a new position in shares of Inovio Pharmaceuticals in the 4th quarter worth about $51,000. Finally, RFG Advisory LLC bought a new stake in Inovio Pharmaceuticals in the 4th quarter valued at about $52,000. Institutional investors own 43.28% of the company’s stock.

NASDAQ:INO opened at $1.84 on Thursday. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 0.05. Inovio Pharmaceuticals has a 1-year low of $1.60 and a 1-year high of $10.33. The firm has a market capitalization of $421.44 million, a price-to-earnings ratio of -1.19 and a beta of 0.80. The stock has a fifty day simple moving average of $3.09 and a 200 day simple moving average of $4.43.

Inovio Pharmaceuticals Company Profile (Get Rating)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Featured Articles